Warren Center For Neuroscience Drug Discovery
-
Jeffrey Conn, founding director of Warren Center for Neuroscience Drug Discovery, named 2021 fellow of American Society for Pharmacology and Experimental Therapeutics
Jeffrey Conn, Lee E. Limbird Chair and professor of pharmacology, is among 16 scientists named 2021 fellows of the American Society for Pharmacology and Experimental Therapeutics. Selection as a fellow of ASPET is an honor bestowed on members who have demonstrated excellence in their efforts to advance pharmacology through scientific achievements, mentorship and service to the society. Read MoreSep 27, 2021
-
Craig Lindsley named to Medicinal Chemistry Division of the American Chemical Society Hall of Fame
Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and director of Vanderbilt’s Warren Center for Neuroscience Drug Discovery, will be inducted to the 2021 class of the Division of Medicinal Chemistry Hall of Fame. Read MoreJun 15, 2021
-
Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes. Read MoreFeb 25, 2021
-
Jerri Rook is awarded the Alzheimer’s Drug Discovery Foundation’s prestigious Melvin R. Goodes prize
Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research. Read MoreNov 2, 2020
-
Warren Center for Neuroscience Drug Discovery names Craig Lindsley as director
Craig Lindsley, the William K. Warren, Jr. Chair and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, effective Dec. 1, 2020. Read MoreOct 20, 2020
-
Turning Heads: The Vanderbilt Brain Institute has emerged as a hub of discovery as neuroscience’s influence expands
The VBI recently marked its 20th anniversary, a span that has seen the institute’s wide-ranging missions—including administering the university’s Neuroscience Graduate Program, as well as postdoctoral training and community outreach—steadily coalesce under a single umbrella. Read MoreAug 5, 2020
-
Committed to Memory: VU319 may hold the key to improving memory loss in Alzheimer’s patients
VU319, an investigational drug product developed by Vanderbilt researchers, targets one of medicine’s most bedeviling challenges: improving memory loss in people with Alzheimer’s disease. Read MoreJul 23, 2020
-
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read MoreJun 16, 2020
-
Leader in Vanderbilt drug discovery efforts, Craig Lindsley named interim editor-in-chief of ACS Pharmacology & Translational Science
Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science." Read MoreJun 12, 2020
-
Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders
Vanderbilt University has received $20 million from The William K. Warren Foundation, located in Tulsa, Oklahoma, to establish the Warren Center for Neuroscience Drug Discovery to support pharmaceutical breakthroughs. Read MoreMay 5, 2020